Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a new treatment option to an indication with little in the armamentarium.